News About: Pharm. Industry


Listed pharmas did well with operating activities in 1st quarter, but got weakened in profitability

Although listed pharmaceutical companies have recorded decent performances with business activities in the 1st quarter, their profitability was analyzed to be weakened for various reasons including non-operating losse...

Merz Korea signs business agreement of ‘Contractubex’ with C&C Healthcare

Follow by the business agreement for ‘Pantogar’ last March, Merz Korea is newly launching an OTC drug business by selecting a new partner for ‘Contractubex,’ a scar treatment. ...

Alvogen Korea’s KRW 4.49 billion sales in 1st quarter, recording losses for the quarter

Alvogen Korea announced on the 15th it recorded KRW 44.91 billion sales in the 1st quarter of 2017, decreased by 1.4% compared to the same quarter of the last year. The company...

Daewoong, “There has been no Nabota counterfeit distributed in Korea so far’

Daewoong Pharmaceutical(CEO Jong-Wook Lee) announced the company was working on distribution of ‘Nabota’ counterfeits on the 12th and revealed an intermediate result that there ...

JW Pharmaceutical acquires license of ‘emicizumab,’ innovative hemophilia A treatment

JW Pharmaceutical acquired a license of a hemophilia A treatment improved in administration convenience in Korea. JW Pharmaceutical(CEO Sung-Kwon Han, Young-Seop Shin) announce...

KHIDI’s ‘Tailored Consulting Program’ for pharmaceutical and biotechnology fields

The Korea Health Industry Development Institute(KHIDI) announced on the 10th it will support consulting expenses for medium and small pharmaceutical companies on R&D planning, licensing, approval and marketing. Appli...

Celltrion reveals Remsima clinical trial result on Crohn’s disease at DDW symposium

At the U.S. Digestive Disease Week(DDW) symposium at Chicago from the 6th to 9th of May, Celltrion revealed a result of the Remsima clinical trial(CT-P12 2.4 CD) on active Crohn’s disease patients and a result of the ...

Pfizer Pharmaceuticals Korea carry out patent support program of ‘Ibrance,’ breast cancer treatment

Pfizer Pharmaceuticals Korea will start a patient support program for ‘Ibrance(generic name: palbociclib),’ a breast cancer therapy. According to the company, it internally had...

Daewoong, “Nabota counterfeits were exposed by investigative agency”

Daewoong Pharmaceutical(CEO Jong-Wook Lee) announced a group of people who made counterfeit ‘Nabota’ products was arrested and confirmed distribution of these products to China....

Kangstem Biotech selected by ‘F1000Prime’ for its publication about rheumatoid arthritis

Kangstem Biotech announced on the 8th that a paper about ‘Furestem-RA,’a rheumatoid arthritis stem cell treatment being developed by the company, was selected as an excellent pa...

TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.